Onsdag 30 Oktober | 09:27:49 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

Tid*
2024-11-12 08:00 Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-06-14 - X-dag ordinarie utdelning SCIB 0.00 SEK
2024-06-13 - Årsstämma
2024-05-31 - Kvartalsrapport 2024-Q1
2024-05-13 - Extra Bolagsstämma 2024
2024-02-22 - Bokslutskommuniké 2023
2023-11-10 - Kvartalsrapport 2023-Q3
2023-08-18 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning SCIB 0.00 SEK
2023-05-17 - Årsstämma
2023-05-10 - Kvartalsrapport 2023-Q1
2023-02-13 - Bokslutskommuniké 2022
2022-11-10 - Kvartalsrapport 2022-Q3
2022-08-18 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning SCIB 0.00 SEK
2022-05-18 - Årsstämma
2022-05-12 - Kvartalsrapport 2022-Q1
2022-02-23 - Bokslutskommuniké 2021
2021-11-11 - Kvartalsrapport 2021-Q3
2021-09-07 - Extra Bolagsstämma 2021
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-19 - X-dag ordinarie utdelning SCIB 0.00 SEK
2021-05-18 - Årsstämma
2021-05-12 - Kvartalsrapport 2021-Q1
2021-02-19 - Bokslutskommuniké 2020
2020-11-12 - Kvartalsrapport 2020-Q3
2020-08-20 - Kvartalsrapport 2020-Q2
2020-06-17 - Årsstämma
2020-05-15 - X-dag ordinarie utdelning SCIB 0.00 SEK
2020-05-05 - Kvartalsrapport 2020-Q1
2020-04-29 - Extra Bolagsstämma 2020
2020-02-21 - Bokslutskommuniké 2019
2019-11-13 - Kvartalsrapport 2019-Q3
2019-08-22 - Kvartalsrapport 2019-Q2
2019-05-17 - X-dag ordinarie utdelning SCIB 0.00 SEK
2019-05-16 - Årsstämma
2019-05-10 - Kvartalsrapport 2019-Q1
2019-02-20 - Bokslutskommuniké 2018
2018-11-13 - Kvartalsrapport 2018-Q3
2018-08-20 - Kvartalsrapport 2018-Q2
2018-05-17 - X-dag ordinarie utdelning SCIB 0.00 SEK
2018-05-16 - Årsstämma
2018-05-09 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-15 - Extra Bolagsstämma 2017
2017-11-10 - Kvartalsrapport 2017-Q3
2017-08-18 - Kvartalsrapport 2017-Q2
2017-05-17 - X-dag ordinarie utdelning SCIB 0.00 SEK
2017-05-16 - Årsstämma
2017-05-10 - Kvartalsrapport 2017-Q1
2017-02-17 - Bokslutskommuniké 2016
2016-11-14 - Kvartalsrapport 2016-Q3
2016-08-19 - Kvartalsrapport 2016-Q2
2016-05-17 - X-dag ordinarie utdelning SCIB 0.00 SEK
2016-05-16 - Årsstämma
2016-05-13 - Kvartalsrapport 2016-Q1
2016-02-19 - Bokslutskommuniké 2015
2015-11-12 - Kvartalsrapport 2015-Q3
2015-08-20 - Kvartalsrapport 2015-Q2
2015-05-06 - Kvartalsrapport 2015-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
SciBase Holding är verksamt inom medicinteknik. Koncernen är specialiserad inom hantering av cancerdiagnostik, främst inriktat mot behandling och upptäckandet av diverse melanom. Bolaget har utvecklat en elektrisk handhållen sond som analyserar mätsignalen för att upptäcka specifika förändringar i kroppens hudvävnad. Huvudkontoret ligger i Stockholm.
2024-05-22 13:30:00

STOCKHOLM, SWEDEN, - May 22, 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], a leading developer of augmented intelligence-based solutions for skin disorders announced today that a new clinical study has been published presenting the improvement that the Nevisense provides over visual and dermoscopic evaluation when clinical evaluations were done by German dermatologists. The article named "Utilizing Data from Electrical Impedance Spectroscopy Significantly Improves the Decision to Biopsy Pigmented Skin Lesions Beyond Clinical Evaluation and Dermoscopy" has been published in the journal "SKIN - The journal of cutaneous medicine". The study included 151 German Dermatologists making a total of 22.197 clinical biopsy decisions. Nevisense was able to improve the rate of correct biopsy choice even after dermoscopic evaluation. While dermoscopy worsened diagnostic accuracy for benign lesions, Nevisense results were able to significantly improve decision making for these lesions as well. This study demonstrates the clinical utility of Nevisense technology for improving melanoma diagnosis.

The article is available through the following link: https://jofskin.org/index.php/skin/article/view/2789

"This is a very important study and results for SciBase as it quantifies the improvement in clinical decision-making possible with Nevisense even compared to dermsocopy. In Germany dermoscopy is standard of care for Dermatologists. The study showed that the addition of Nevisense further improved dermatologists' clinical performance. This is another publication that shows that Nevisense has a significant role in the diagnostic process to correctly identify malignant lesions in order to not miss any melanomas", says Pia Renaudin, CEO of SciBase.

For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802, e-mail: pia.renaudin@scibase.com
Certified Advisor (CA):

Vator Securities

Tel: +46 8 580 065 99

Email: ca@vatorsec.se

About SciBase
 

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at www.scibase.com. All press releases and financial reports can be found here: http://investors.scibase.se/en/pressreleases